KTTA

Pasithea Therapeutics Corp. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website asithea.com
Employees(FY) 15
ISIN US70261F2020

Performance

-5.06%

-26.16%

-31.51%

-51.67%

-56.89%

YTD

-50.36%

Profile

Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for Central Nervous System disorders, RASopathies, and other diseases. It operates through two segments, Therapeutics and Clinics. The company provides business support services to anti-depression clinics, entities, and registered healthcare providers. Its lead product candidate PAS-004, a next-generation mitogen-activated protein kinase, or MEK inhibitor designed to be macrocyclic for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 and Noonan syndrome, as well as lamin A/C cardiomyopathy and oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; PAS-002, for the treatment multiple sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Advanced Technical Analysis

Technical Analysis of KTTA 2024-11-20

The Moving Average Score of 10 indicates a strong bearish sentiment, while the Oscillators Score of 56 suggests a neutral stance. Overall, the Technical Score of 33 reinforces the bearish outlook, indicating that the stock is currently facing downward pressure despite some neutral oscillation signals.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of KTTA

Stock Rank

Recent News & Updates

2024-11-19 18:02
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer(Globenewswire)
2024-09-26 06:44
Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules(Globenewswire)
2024-09-25 19:02
Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer(Globenewswire)
2024-09-08 20:01
Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies(Globenewswire)
2024-09-02 20:02
Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board(Globenewswire)
2024-08-27 21:11
Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference(Globenewswire)
2024-06-25 00:52
KTTA Stock Earnings: Pasithea Therapeutics Reported Results for Q4 2023(Investorplace)
2024-06-12 18:59
Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for PAS-004 in Ongoing Phase 1 Clinical Trial(Globenewswire)
2024-05-27 18:59
Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting(Globenewswire)
2024-05-14 21:53
KTTA Stock Earnings: Pasithea Therapeutics Reported Results for Q1 2024(Investorplace)
2024-04-28 19:59
Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting(Globenewswire)
2024-04-23 19:59
Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers(Globenewswire)
2024-04-14 23:00
11 Undervalued Stocks for Less Than $50 in April 2024(Investopedia)
2024-02-12 18:59
Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004(Globenewswire)
2024-01-07 18:59
Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position(Globenewswire)
2024-01-01 19:35
Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients(Globenewswire)
2023-12-28 04:00
Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023(Globenewswire)
2023-12-19 04:19
Pasithea Therapeutics Announces Results from 2023 Annual Meeting(Globenewswire)
2023-12-12 20:03
Why Is Pasithea Therapeutics (KTTA) Stock Down 12% Today?(Investorplace)
2023-12-10 22:18
Why Is Pasithea Therapeutics (KTTA) Stock Up 105% Today?(Investorplace)
2023-12-10 19:01
Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models(Globenewswire)
2023-11-29 03:27
Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders(Globenewswire)
2023-11-28 18:59
Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development(Globenewswire)
2023-11-08 18:59
Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets 5 1 Integrin for the Treatment of both Sporadic and Familial ALS(Globenewswire)
2023-09-13 20:30
Pasithea Therapeutics Corp. Announces Final Results of Tender Offer(Yahoo Finance)
2023-09-07 04:14
Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference(Yahoo Finance)
2023-07-31 19:59
Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in 5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting 5 integrin results in improved survival (Yahoo Finance)
2023-07-30 18:00
The Psychedelics Stock Universe Is Shrinking, Despite the Hype(Yahoo Finance)
2023-07-19 20:43
Pasithea Therapeutics Announces Intention to Commence a $4.0Â Million Tender Offer for its Common Stock at Price of $0.70 per Share in Cash(Yahoo Finance)
2023-07-19 20:40
Pasithea Therapeutics Special Committee Rejects Unsolicited Bid from Lucy Scientific Discovery, Inc.(Yahoo Finance)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.